Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption

Journal of Medicinal Chemistry

Volumn 48, Issue 8, 2005, Pages 2957-2963

  Sanders, John M ^a   Song, Yongcheng ^a   Chan, Julian M W ^a   Zhang, Yonghui ^a   Jennings, Samuel ^a   Kosztowski, Thomas ^a   Odeh, Sarah ^a   Flessner, Ryan ^a   Schwerdtfeger, Christine ^a   Kotsikorou, Evangelia ^a   Meints, Gary A ^a   Gómez, Aurora Ortiz ^b   González Pacanowska, Dolores ^b   Raker, Amy M ^c   Wang, Hong ^c   Van Beek, Ermond R ^d   Papapoulos, Socrates E ^d   Morita, Craig T ^c   Oldfield, Eric ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^c UNIVERSITY OF IOWA   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ENZYME INHIBITOR; GERANYLTRANSFERASE; GERANYLTRANSFERASE INHIBITOR; PAMIDRONIC ACID; PYRIDINIUM 1 YL BISPHOSPHONATE DERIVATIVE; PYRIDINIUM DERIVATIVE; RISEDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANIMAL CELL; ARTICLE; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; DICTYOSTELIUM DISCOIDEUM; DRUG DESIGN; DRUG INHIBITION; DRUG POTENCY; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; LEISHMANIA MAJOR; NONHUMAN; OSTEOLYSIS; T LYMPHOCYTE ACTIVATION;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; BONE RESORPTION; CALCIUM; DICTYOSTELIUM; DIPHOSPHONATES; GERANYLTRANSTRANSFERASE; HUMANS; LEISHMANIA MAJOR; METATARSAL BONES; MICE; MODELS, MOLECULAR; PYRIDINIUM COMPOUNDS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; TRYPANOCIDAL AGENTS;

EID: 20944447015     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040209d     Document Type: Article

References (57)

1. Sambrook, P. N.; Geusens, P.; Ribot, C.; Solimano, J. A.; Ferrer-Barriendos, J.; Gaines, K.; Verbruggen, N.; Melton, M. E. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (EFficacy of FOSAMAX versus EVISTA Comparison Trial) International. J. Intern. Med. 2004, 255, 503-511.
2. Vasireddy, S.; Talwakar, A.; Miller, H.; Mehan, R.; Swinson, D. R. Patterns of pain in Paget's disease of bone and their outcomes on treatment with pamidronate. Clin. Rheumatol. 2003, 22, 376-380.
3. Dawson, N. A. Therapeutic benefit of bisphosphonates in the management of prostate cancer-related bone disease. Expert. Opin. Pharmacother. 2003, 4, 705-716.
4. Rosen, L. S.; Gordon, D. H.; Dugan, W. Jr.; Major, P.; Eisenberg, P. D.; Provencher, L.; Kaminski, M.; Simeone, J.; Seaman, J.; Chen, B. L.; Coleman, R. E. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004, 100, 36-43.
5. Cromartie, T. H.; Fisher, K. J.; Grossman, J. N. The discovery of a novel site of action for herbicidal bisphosphonates. Pesticide Biochem. Phys. 1999, 63, 114-126.
6. Cromartie, T. H.; Fisher, K. J. Method of controlling plants by inhibition of farnesyl pyrophosphate synthase. U.S. Patent 5,756,423, May 26, 1998.
7. van Beek, E.; Pieterman, E.; Cohen, L.; Löwik, C.; Papapoulos, S. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem. Biophys. Res. Commun. 1999, 255, 491-494.
8. van Beek, E.; Pieterman, E.; Cohen, L.; Löwik, C.; Papapoulos, S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem. Biophys. Res. Commun. 1999, 264, 108-111.
9. Keller, R. K.; Fliesler, S. J. Mechanism of aminobisphosphonate action: characterization of alendronate inhibition of the isoprenoid pathway. Biochem. Biophys. Res. Commun. 1999, 266, 560-563.
10. Bergstrom, J. D.; Bostedor, R. G.; Masarachia, P. J.; Reszka, A. A.; Rodan, G. Mechanism of aminobisphosphonate action: characterization of alendronate inhibition of the isoprenoid pathway. Arch. Biochem. Biophys. 2000, 373, 231-241.
11. Grove, J. E.; Brown, R. J.; Watts, D. J. The intracellular target for the antiresorptive aminobisphosphonate drugs in Dictyostelium discoideum is the enzyme farnesyl diphosphate synthase. J. Bone Miner. Res. 2000, 15, 971-981.
12. Dunford, J. E.; Thompson, K.; Coxon, F. P.; Luckman, S. P.; Hahan, F. M.; Poulter, C. D.; Ebetino, F. H.; Rogers, M. J. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 2001, 296, 235-242.
13. Luckman, S. P.; Hughes, D. E.; Coxon, F. P.; Graham, R.; Russell, G.; Rogers, M. J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 1998, 13, 581-589.
14. Fisher, J. E.; Rogers, M. J.; Halasy, J. M.; Luckman, S. P.; Hughes, D. E.; Masarachia, P. J.; Wesolowski, G.; Russell, R. G.; Rodan, G. A.; Reszka, A. A. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 133-138.
15. van Beek, E.; Löwik, C.; van der Pluijm, G.; Papapoulos, S. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates. J. Bone Miner. Res. 1999, 14, 722-729.
16. Montalvetti, A.; Bailey, B. N.; Martin, M. B.; Severin, G. W.; Oldfield, E.; Docampo, R. Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. J. Biol. Chem. 2001, 276, 33930-33937.
17. Sanders, J. M.; Gómez, A. O.; Mao, J.; Meints, G. A.; van Brussel, E. M.; Burzynska, A.; Kafarski, P.; González-Pacanowska, D.; Oldfield, E. 3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates. J. Med. Chem. 2003, 46, 5171-5183.
18. Martin, M. B.; Grimley, J. S.; Lewis, J. C.; Heath, H. T. III; Bailey, B. N.; Kendrick, H.; Yardley, V.; Caldera, A.; Lira, R.; Urbina, J. A.; Moreno, S. N.; Docampo, R.; Croft, S. L.; Oldfield, E. Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: A potential route to chemotherapy. J. Med. Chem. 2001, 44, 909-916.
19. Martin, M. B.; Sanders, J. M.; Kendrick, H.; de Luca-Fradley, K.; Lewis, J. C.; Grimley, J. S.; van Brussel, E. M.; Olsen, J. R.; Meints, G. A.; Burzynska, A.; Kafarski, P.; Croft, S. L.; Oldfield, E. Activity of bisphosphonates against Trypanosoma brucei rhodesiense. J. Med. Chem. 2002, 45, 2904-2914.
20. 31P NMR of apicomplexans and the effects of risedronate on Cryptosporidium parvum growth. Biochem. Biophys. Res. Commun. 2001, 284, 632-637.
21. Ghosh, S.; Chan, J. M.; Lea, C. R.; Meints, G. A.; Lewis, J. C.; Tovian, Z. S.; Flessner, R. M.; Loftus, T. C.; Bruchhaus, I.; Kendrick, H.; Croft, S. L.; Kemp, R. G.; Kobayashi, E. Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo. J. Med. Chem. 2004, 47, 175-187.
22. Yardley, V.; Khan, A. A.; Martin, M. B.; Slifer, T. R.; Araujo, F. G.; Moreno, S. N.; Docampo, R.; Croft, S. L.; Oldfield, E. In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii. Antimicrob. Agents Chemother. 2002, 46, 929-931.
23. Rodriguez, N.; Bailey, B. N.; Martin, M. B.; Oldfield, E.; Urbina, J. A.; Docampo, R. Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate. J. Infect. Dis. 2002, 186, 138-140.
24. Garzoni, L. R.; Caldera, A.; Meirelles, M. N. L.; de Castro, S. L.; Meints, G.; Docampo, R.; Oldfield, E.; Urbina, J. A. Selective in vitro effects of the farnesyl pyrophosphate synthase inhibitor risedronate on Trypanosoma cruzi. Intl. J. Antimicrob. Agents 2004, 23, 273-285.
25. Garzoni, L. R.; Waghabi, M. C.; Baptista, M. M.; de Castro, S. L.; Meirelles, M. N. L.; Britto, C.; Docampo, R.; Oldfield, E.; Urbina, J. A. Antiparasitic activity of risedronate in a murine model of acute Chagas' disease. Int. J. Antimicrob. Agents 2004, 23, 286-290.
26. Wang, L.; Kamath, A.; Das, H.; Li, L.; Bukowski, J. F. Antibacterial effect of human Vγ2Vδ2 T cells in vivo. J. Clin. Invest. 2001, 108, 1349-1357.
27. Kunzmann, V.; Bauer, E.; Feurle, J.; Weissinger, F.; Tony, H. P.; Wilhelm, M. Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000, 96, 384-392.
28. Kato, Y.; Tanaka, Y.; Miyagawa, F.; Yamashita, S.; Minato, N. Targeting of tumor cells for human γδ T cells by nonpeptide antigens. J. Immunol. 2001, 167, 5092-5098.
29. Thompson, K.; Rogers, M. J. Statins prevent bisphosphonate-induced γδ-T-cell proliferation and activation in vitro. J. Bone Miner. Res. 2004, 19, 278-288.
30. Sanders, J. M.; Ghosh, S.; Chan, J. M. W.; Meints, G.; Wang, H.; Raker, A. M.; Song, Y.; Colantino, A.; Burzynska, A.; Kafarski, P.; Morita, C. T.; Oldfield, E. Quantitative structure-activity relationships for γδ T cell activation by bisphosphonates. J. Med. Chem. 2004, 47, 375-384.
31. Wilhelm, M.; Kunzmann, V.; Eckstein, S.; Reimer, P.; Weissinger, F.; Ruediger, T.; Tony, H. P. γδ T cells for immune therapy of patients with lymphoid malignancies. Blood 2003, 102, 200-206.
32. Kotsikorou, E.; Oldfield, E. A quantitative structure-activity relationship and pharmacophore modeling investigation of aryl-X and heterocyclic bisphosphonates as bone resorption agents. J. Med. Chem. 2003, 46, 2932-2944.
33. Cramer, R. D. III; Patterson, D. E.; Bunce, J. D. Recent advances in comparative molecular field analysis (CoMFA). Prog. Clin. Biol. Res. 1989, 291, 161-165.
34. Klebe, G.; Abraham, U.; Mietzner, T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem. 1994, 37, 4130-4146.
35. Catalyst, version 4.8; Accelrys Inc., 9685 Scranton Rd., San Diego, CA 92121.
36. (a) Golomb, G.; Danenberg, H. Treatment of restenosis. US Patent 6,719,998, 2004.
37. (b) Danenberg, H.; Golomb, G. Treatment of restenosis. World Patent WO0003677, 2000.
38. (c) Grossmann, G.; Grossmann, A.; Ohms, G.; Breuer, E.; Chen, R.; Golomb, G.; Cohen, H.; Hägele, G.; Classen, R. Solid-state NMR of bisphosphonates adsorbed on hydroxyapatite. Magn. Reson. Chem. 2000, 38, 11-16.
39. (d) Cohen, H.; Alfer'ev, I. S.; Monkkonen, J.; Seibel, M. J.; Pinto, T.; Ezra, A.; Solomon, V.; Stepensky, D.; Sagi, H.; Ornoy, A.; Patlas, N.; Hagele, G.; Hoffman, A.; Breuer, E.; Golomb G. Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine (ISA-13-1)-a novel bisphosphonate. Pharm. Res. 1999, 16, 1399-1406.
40. (e) Patlas, N.; Golomb, G.; Yaffe, P.; Pinto, T.; Breuer, E.; Ornoy, A. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 1999, 60, 68-73.
41. (f) Cohen, H.; Solomon, V.; Alfer'ev, I. S.; Breuer, E.; Ornoy, A.; Patlas, N.; Eidelman, N.; Hagele, G.; Golomb G. Bisphosphonates and tetracycline: experimental models for their evaluation in calcium-related disorders. Pharm. Res. 1998, 15, 606-613.
42. (g) Klein, B. Y.; Ben-Bassat, H.; Breuer, E.; Solomon, V.; Golomb, G. Structurally different bisphosphonates exert opposing effects on alkaline phosphatase and mineralization in marrow osteoprogenitors. J. Cell. Biochem. 1998, 68, 186-194.
43. (h) Alfer'ev, I. S.; Breuer, E.; Golomb, G.; Ornoy, A. Novel bisphosphonates, process for their preparation and pharmaceutical compositions containing them. World Patent WO9708178, 1997.
44. (i) Breuer, E.; Golomb, G.; Amidon, G. L.; Alfer'ev, I. S.; Rozen, N. E.-H.; Friedman-Ezra, A. Phosphonates, bisphosphonates and pharmaceutical compositions containing them. World Patent WO9631227, 1996.
45. (j) Cohen, H.; Breuer, E.; Chen, R.; Solomon, V.; Ornoy, A.; Patlas, N.; Pinto, T.; Golomb, G. Synthesis and evaluation of nitrogen-containing novel bisphosphonates for calcium-related disorders. Pharm. Res. 1996, 13, s-139.
46. (k) Alfer'ev, I. S.; Mikhalin, N. V. Reactions of vinylidenediphosphonic acid with nucleophiles 5. Addition of heterocyclic amines and trimethylamine to vinylidenediphosphonic acid. Russ. Chem. Bull. 1995, 44, 1528-1530.
47. (l) Alfer'ev, I. S.; Mikhalin, N. V.; Novikova, V. M.; Kozlov, V. A. Substituted ammonioethylidene-1,1-diphosphonic acids with immunosuppressant activity. Russian Patent SU1089953, 1995.
48. van Beek, E. R.; Löwik, C. W. G. M.; Ebetino, F. H.; Papapoulos, S. E. Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: Structure-activity relationships. Bone 1998, 23, 437-442.
49. Gaussian 03, Revision C.02, Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Montgomery, Jr., J. A.; Vreven, T.; Kudin, K. N.; Burant, J. C.; Millam, J. M.; Iyengar, S. S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J. E.; Hratchian, H. P.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Ayala, P. Y.; Morokuma, K.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; Farkas, O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Ortiz, J. V.; Cui, Q.; Baboul, A. G.; Clifford, S.; Cioslowski, J.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Gonzalez, C.; Pople, J. A.; Gaussian, Inc., Wallingford, CT, 2004.
50. Besler, B. H.; Merz, K. M.; Kollman, P. A. Atomic charges derived from semiempirical methods. J. Comput. Chem. 1990, 11, 431-439.
51. Singh, U. C.; Kollman, P. A. An approach to computing electrostatic charges for molecules. J. Comput. Chem. 1984, 5, 129-145
52. Miyaura, N.; Yanagi, T.; Suzuki, A. The palladium-catalyzed cross-coupling reaction of phenylboronic acid with haloarenes in the presence of bases. Synth. Commun. 1981, 11, 513-519.
53. NAr displacements studies by diamines: bis(aminoalkyl)aminobenz[g]-isoquinoline-5, 10-diones. J. Fluorine Chem. 1998, 90, 139-147.
54. Zhang, L.; Liang, F.; Sun, L.; Hu, Y.; Hu, H. A novel and practical synthesis of 3-unsubstituted indolizines. Synthesis 2000, 1733-1737.
55. Harel, Z.; Kovalevski-Liron, E.; Lidor-Hadas, R.; Lifshitz-Liron, R. Use of certain diluents for making bisphosphonic acids. World Patent WO03097655, November 27, 2003.
56. Rogers, M. J.; Watts, D. J.; Russell, R. G.; Ji, X.; Xiong, X.; Blackburn, G. M.; Bayless, A. V.; Ebetino, F. H. Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold Dictyostelium discoideum. J. Bone Miner. Res. 1994, 9, 1029-1039.
57. van Beek, E. R.; Cohen, L. H.; Leroy, I. M.; Ebetino, F. H.; Löwik, C. W.; Papapoulos, S. E. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 2003, 33, 805-11.